UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 2, 2017

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At August 7, 2017, 5,947,349,054 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and six months ended July 2, 2017 and July 3, 2016

Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 2, 2017 and

July 3, 2016

Condensed Consolidated Balance Sheets as of July 2, 2017 and December 31, 2016

Condensed Consolidated Statements of Cash Flows for the six months ended July 2, 2017 and July 3, 2016

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

43

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

44

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

103

Item 4.

Controls and Procedures

103

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

104

Item 1A.

Risk Factors

104

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

105

Item 3.

Defaults Upon Senior Securities

105

Item 4.

Mine Safety Disclosures

105

Item 5.

Other Information

105

Item 6.

Exhibits

106

Signature

107

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2016 Financial Report

Financial Report for the fiscal year ended December 31, 2016, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016

2016 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2016

AAV

Adeno-Associated Virus

ACA (Also referred to as U.S. Healthcare Legislation)

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

ALK

anaplastic lymphoma kinase

Allergan

Allergan plc

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Anacor

Anacor Pharmaceuticals, Inc.

Astellas

Astellas Pharma U.S., Inc.

ASU

Accounting Standards Update

ATM-AVI

aztreonam-avibactam

Bamboo

Bamboo Therapeutics, Inc.

BMS

Bristol-Myers Squibb Company

CDC

U.S. Centers for Disease Control and Prevention

Cellectis

Cellectis SA

Citibank

Citibank N.A.

Developed Markets

U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand

EEA

European Economic Area

EH

Essential Health

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey

EPS

earnings per share

EU

European Union

EURIBOR

Euro Interbank Offered Rate

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GIST

gastrointestinal stromal tumors

GPD

Global Product Development

HER2-

human epidermal growth factor receptor 2-negative

HIS

Hospira Infusion Systems

Hisun

Zhejiang Hisun Pharmaceuticals Co., Ltd.

Hisun Pfizer

Hisun Pfizer Pharmaceuticals Company Limited

Hospira

Hospira, Inc.

HR+

hormone receptor-positive

ICU Medical

ICU Medical, Inc.

IH

Innovative Health

IPR&D

in-process research and development

IRS

U.S. Internal Revenue Service

IV

intravenous

Janssen

Janssen Biotech Inc.

King

King Pharmaceuticals, Inc.

LDL

low density lipoprotein

LIBOR

London Interbank Offered Rate

Lilly

Eli Lilly & Company

LOE

loss of exclusivity

MCO

Managed Care Organization

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

Medivation

Medivation, Inc.

Merck

Merck & Co., Inc.

Meridian

Meridian Medical Technologies, Inc.

Moody s

Moody s Investors Service

NDA

new drug application

NovaQuest

NovaQuest Co-Investment Fund V, L.P.

NSCLC

non-small cell lung cancer

NYSE

New York Stock Exchange

OPKO

OPKO Health, Inc.

OTC

over-the-counter

PBM

Pharmacy Benefit Manager

Pharmacia

Pharmacia Corporation

PP&E

Property, plant & equipment

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended July 2, 2017

RCC

renal cell carcinoma

R&D

research and development

RPI

RPI Finance Trust

Sandoz

Sandoz, Inc., a division of Novartis AG

Sangamo

Sangamo Therapeutics, Inc.

SEC

U.S. Securities and Exchange Commission

SFJ

SFJ Pharmaceuticals Group

S&P

Standard and Poor s

Teuto

Laborat rio Teuto Brasileiro S.A.

U.K.

United Kingdom

U.S.

United States

ViiV

ViiV Healthcare Limited

WRD

Worldwide Research and Development

Zoetis

Zoetis Inc.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

July 2,

2017

July 3,

2016

July 2,

2017

July 3,

2016

Revenues

12,896

13,147

25,675

26,152

Costs and expenses:

Cost of sales(a)

2,663

3,174

5,134

6,026

Selling, informational and administrative expenses(a)

3,425

3,471

6,733

6,856

Research and development expenses(a)

1,780

1,748

3,487

3,478

Amortization of intangible assets

1,208

961

2,394

1,966

Restructuring charges and certain acquisition-related costs

70

316

228

457

Other (income)/deductions net

(66

1,068

(68

1,398

Income from continuing operations before provision for taxes on income

3,815

2,410

7,767

5,971

Provision for taxes on income(b)

739

347

1,560

861

Income from continuing operations(b)

3,077

2,062

6,207

5,110

Discontinued operations net of tax

Net income before allocation to noncontrolling interests(b)

3,078

2,063

6,208

5,111

Less: Net income attributable to noncontrolling interests

16

14

25

Net income attributable to Pfizer Inc.(b)

3,073

2,047

6,194

5,085

Earnings per common share basic(b):

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.52

0.34

1.04

0.83

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.52

0.34

1.04

0.83

Earnings per common share diluted(b):

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.51

0.33

1.02

0.82

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.51

0.33

1.02

0.82

Weighted-average shares basic

5,958

6,068

5,982

6,110

Weighted-average shares diluted

6,037

6,149

6,065

6,188

Cash dividends paid per common share

0.32

0.30

0.64

0.60

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

(b)

Amounts for the three and six months ended July 3, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies Adoption of New Accounting Standards.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS OF DOLLARS)

July 2,

2017

July 3,

2016

July 2,

2017

July 3,

2016

Net income before allocation to noncontrolling interests

3,078

2,063

6,208

5,111

Foreign currency translation adjustments, net

247

515

474

581

Reclassification adjustments(a)

111

112

358

515

586

581

Unrealized holding losses on derivative financial instruments, net

(90

(571

(99

(845

Reclassification adjustments for realized (gains)/losses(b)

(208

469

(449

130

(297

(102

(548

(714

Unrealized holding gains on available-for-sale securities, net

164

350

314

479

Reclassification adjustments for realized (gains)/losses(b)

(40

(226

97

(16

124

124

412

463

Benefit plans: actuarial gains/(losses), net

61

(19

62

(19

Reclassification adjustments related to amortization(c)

145

139

308

278

Reclassification adjustments related to settlements, net(c)

(1

22

51

48

Other

(80

(57

(35

(18

124

85

385

288

Benefit plans: prior service (costs)/credits and other, net

(2

87

(2

87

Reclassification adjustments related to amortization(c)

(46

(41

(91

(81

Reclassification adjustments related to curtailments, net(c)

(4

(11

(6

Other

(52

48

(104

Other comprehensive income, before tax

258

669

732

624

Tax provision/(benefit) on other comprehensive income(d)

(163

36

(138

(5

Other comprehensive income before allocation to noncontrolling interests

421

633

870

629

Comprehensive income before allocation to noncontrolling interests

3,499

2,696

7,078

5,740

Less: Comprehensive income attributable to noncontrolling interests

13

21

29

24

Comprehensive income attributable to Pfizer Inc.

3,486

2,676

7,049

5,715

(a)

The foreign currency translation adjustments reclassified into Other (income)/deductions net in the condensed consolidated statements of income primarily result from the agreement to sell our 40% ownership investment in Teuto. See Note 2D. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments: Equity-Method Investments.

(b)

Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income.

(c)

Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.

(d)

See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

July 2,

2017

December 31,

2016

(Unaudited)

Assets

Cash and cash equivalents

2,585

2,595

Short-term investments

11,748

15,255

Trade accounts receivable, less allowance for doubtful accounts: 2017 $579; 2016 $609

9,476

8,225

Inventories

7,584

6,783

Current tax assets

3,113

3,041

Other current assets

1,877

2,249

Assets held for sale

801

Total current assets

36,385

38,949

Long-term investments

7,008

7,116

Property, plant and equipment, less accumulated depreciation: 2017 $15,506; 2016 $14,807

13,386

13,318

Identifiable intangible assets, less accumulated amortization

51,348

52,648

Goodwill

55,014

54,449

Noncurrent deferred tax assets and other noncurrent tax assets

1,952

1,812

Other noncurrent assets

3,466

3,323

Total assets

168,558

171,615

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2017 $3,072; 2016 $4,225

9,514

10,688

Trade accounts payable

3,439

4,536

Dividends payable

1,904

1,944

Income taxes payable

552

437

Accrued compensation and related items

1,625

2,487

Other current liabilities

10,148

11,023

Total current liabilities

27,182

31,115

Long-term debt

34,191

31,398

Pension benefit obligations, net

5,371

6,406

Postretirement benefit obligations, net

1,705

1,766

Noncurrent deferred tax liabilities

30,879

30,753

Other taxes payable

4,096

4,000

Other noncurrent liabilities

6,440

6,337

Total liabilities

109,863

111,776

Commitments and Contingencies

Preferred stock

23

24

Common stock

463

461

Additional paid-in capital

83,373

82,685

Treasury stock

(89,416

(84,364

Retained earnings

74,107

71,774

Accumulated other comprehensive loss

(10,181

(11,036

Total Pfizer Inc. shareholders equity

58,368

59,544

Equity attributable to noncontrolling interests

326

296

Total equity

58,694

59,840

Total liabilities and equity

168,558

171,615

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(MILLIONS OF DOLLARS)

July 2,

2017

July 3,

2016

Operating Activities

Net income before allocation to noncontrolling interests

6,208

5,111

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

3,129

2,812

Asset write-offs and impairments

97

983

Loss on sale of HIS net assets

64

Deferred taxes from continuing operations

320

(10

Share-based compensation expense

388

387

Benefit plan contributions in excess of expense

(1,079

(857

Other adjustments, net

(433

170

Other changes in assets and liabilities, net of acquisitions and divestitures(a)

(3,853

(3,182

Net cash provided by operating activities

4,841

5,414

Investing Activities

Purchases of property, plant and equipment

(806

(702

Purchases of short-term investments

(2,394

(8,744

Proceeds from redemptions/sales of short-term investments

3,520

14,757

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less

3,424

(249

Purchases of long-term investments

(1,663

(3,126

Proceeds from redemptions/sales of long-term investments

1,539

2,427

Acquisitions of businesses, net of cash acquired

(1,000

(4,616

Acquisitions of intangible assets

(41

(96

Other investing activities, net

455

26

Net cash provided by/(used in) investing activities

3,034

(323

Financing Activities

Proceeds from short-term borrowings

4,799

2,307

Principal payments on short-term borrowings

(5,110

(2,291

Net proceeds from short-term borrowings with original maturities of three months or less

261

2,182

Proceeds from issuance of long-term debt

5,273

5,031

Principal payments on long-term debt

(4,473

(4,317

Purchases of common stock

(5,000

(5,000

Cash dividends paid

(3,855

(3,675

Proceeds from exercise of stock options

411

696

Other financing activities, net(a)

(228

(186

Net cash used in financing activities

(7,922

(5,253

Effect of exchange-rate changes on cash and cash equivalents

37

(68

Net decrease in cash and cash equivalents

(10

(230

Cash and cash equivalents, beginning

2,595

3,641

Cash and cash equivalents, end

2,585

3,411

Supplemental Cash Flow Information

Non-cash transactions:

Receipt of ICU Medical common stock(b)

428

Promissory note from ICU Medical(b)

75

Cash paid (received) during the period for:

Income taxes

1,121

1,111

Interest

881

903

Interest rate hedges

(226

(306

(a)

Amounts for the three and six months ended July 3, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.

(b)

In connection with the sale of HIS net assets to ICU Medical, on February 3, 2017, Pfizer received 3.2 million newly issued shares of ICU Medical common stock valued at $428 million and a promissory note in the amount of $75 million. For additional information, see Note 2B. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments: Sale of Hospira Infusion Systems Net Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.

We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.

The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 28, 2017 and May 29, 2016. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and six months ended July 2, 2017 and July 3, 2016.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2016 Form 10-K.

We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Beginning in the second quarter of 2016, we reorganized our operating segments to reflect that we manage our innovative pharmaceutical and consumer healthcare operations as one business segment, IH. For additional information, see Note 13 and Notes to Consolidated Financial Statements Note 18. Segment, Geographic and Other Revenue Information in Pfizer s 2016 Financial Report.

Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.

Our recent significant business development activities include:

On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The operating results of HIS are included in the condensed consolidated statement of income and EH s operating results through February 2, 2017 and, therefore, our financial results, and EH s operating results, for the second quarter of 2017 do not reflect any contribution from HIS global operations, while our financial results, and EH s operating results, for the second quarter of 2016 reflect three months of HIS global operations. Our financial results, and EH s operating results, for the first six months of 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH s operating results, for the first six months of 2016 reflect six months of HIS global operations. Assets and liabilities associated with HIS are presented as held for sale in the condensed consolidated balance sheet as of December 31, 2016. The HIS assets held for sale are reported in Assets held for sale and HIS liabilities held for sale are reported in Other current liabilities.

On December 22, 2016, which falls in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, and EH s operating results, for the second quarter and first six months of 2017 reflect approximately three months and five months, respectively, of the small molecule anti-infectives business acquired from AstraZeneca.

On September 28, 2016, we acquired Medivation for $81.50 per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. Therefore, Medivation operations are reflected in our financial results, IH s operating results, and cash flows for the second quarter and first six months of 2017, but not for the second quarter and first six months of 2016.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

On June 24, 2016, we acquired Anacor for $99.25 per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor. Therefore, Anacor operations are reflected in our financial results, IH s operating results, and cash flows for the second quarter and first six months of 2017, but for only five days in the second quarter and first six months of 2016.

For additional information, see Note 2 and Notes to Consolidated Financial Statements Note 2. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments in Pfizer s 2016 Financial Report.

B. Adoption of New Accounting Standards

In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of share-based compensation to be recognized as a component of the Provision for taxes on income, whereas excess tax benefits or deficiencies previously were recognized in Additional paid-in capital. The net tax benefit for the Company was $28 million for the second quarter of 2016 and $50 million for the first six months of 2016. Also, in the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit.

Another element of the new accounting standard requires that we now present excess tax benefits as operating activities in our consolidated statements of cash flow. We elected to adopt this presentation on a prospective basis as of January 1, 2016. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification was required to be adopted retrospectively. As a result, $51 million of cash outflows for the first six months of 2016 was reclassified from operating activities to financing activities in the condensed consolidated statement of cash flows. For additional information, see Notes to Consolidated Financial Statements Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards included in our 2016 Financial Report.

We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our condensed consolidated financial statements from adopting this standard.

We adopted a new standard as of January 1, 2017 related to inventory. The new guidance requires that inventory be measured at the lower of cost or net realizable value, which is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. There was no material impact to our condensed consolidated financial statements from adopting this standard.

Note 2. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments